PMVP · CIK 0001699382 · operating
PMV Pharmaceuticals is a precision oncology company focused on discovering and developing therapies targeting p53 mutations in cancer. The company's approach centers on correcting p53 misfolding caused by specific mutations, with particular emphasis on the Y220C mutation. Its lead product candidate, rezatapopt, is an orally available small molecule designed to selectively restore p53 function in tumors with this mutation while preserving wild-type p53 activity in healthy cells.
The company operates as a clinical-stage biopharmaceutical entity with a pipeline focused on tumor-agnostic applications for p53-mutant cancers. PMV Pharmaceuticals does not currently generate product revenues and operates as a development-stage company advancing its clinical programs.
Based in Princeton, New Jersey, PMV Pharmaceuticals operates with a small team of 47 full-time employees. The company was incorporated in Delaware in 2013 and is publicly traded on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.14 | $-1.14 | +20.8% | |
| 2023 | $-1.44 | $-1.44 | +10.6% | |
| 2022 | $-1.61 | $-1.61 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |